Induction of apoptosis of human B-CLL and ALL cells by a novel retinoid and its nonretinoidal analog

Blood

Volumn 100, Issue 8, 2002, Pages 2917-2925

  Zhang, Yuxiang ^a,b,c,d,e   Dawson, Marcia I ^a,b,c,d,e   Mohammad, Ramzi ^a,b,c,d,e   Rishi, Arun K ^a,b,c,d,e   Farhana, Lulu ^a,b,c,d,e   Feng, Kai Chia ^a,b,c,d,e   Leid, Mark ^a,b,c,d,e   Peterson, Valerie ^a,b,c,d,e   Zhang, Xiao Kun ^a,b,c,d,e   Edelstein, Mark ^a,b,c,d,e   Eilander, David ^a,b,c,d,e   Biggar, Sandra ^a,b,c,d,e   Wall, Nathan ^a,b,c,d,e   Reichert, Uwe ^a,b,c,d,e   Fontana, Joseph A ^a,b,c,d,e  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c BURNHAM INSTITUTE   (United States)

^d OREGON STATE UNIVERSITY   (United States)

^e Galderma R and D   (France)

Author keywords

[No Author keywords available]

Indexed keywords

6 [3 (1 ADAMANTYL) 4 HYDROXYPHENYL] 2 NAPHTHOIC ACID; CASPASE 2; CASPASE 3; MITOGEN ACTIVATED PROTEIN KINASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN MCL 1; RETINOIC ACID RECEPTOR; RETINOID;

ACUTE LYMPHOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; LEUKEMIA CELL; LYMPHATIC LEUKEMIA; PRIORITY JOURNAL; SCID MOUSE;

EID: 0037108561     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V100.8.2917     Document Type: Article

References (66)

1. Foon KA, Rai KR, Gale RP. Chronic lymphocytic leukemia: new insights into biology and therapy. Ann Int Med. 1990;113:525-539.
2. Reed JC. Molecular biology of chronic lymphocytic leukemia. Semin Oncology. 1998;25:11-18.
3. Kitada S, Anderson J, Akar S, et al. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with in vitro and in vivo chemoresponses. Blood. 1998;91:3379-3389.
4. McConkey DJ, Chandra J, Wright S, et al. Apoptosis sensitivity in chronic lymphocytic leukemia is determined by endogenous endonuclease content and relative expression of Bcl-2 and BAX. J Immunol. 1996;156:2624-2630.
5. Schena M, Larson LG, Gottardi D, et al. Growth-and differentiation-associated expression of bcl-2 in B-chronic lymphocytic leukemia cells. Blood. 1992;79:2981-2989.
6. Thomas A, El Rouby S, Reed JC, Krajewski S, Potmesil M, Newcomb EW. Drug-induced apoptosis in B-cell chronic lymphocytic leukemia: relationship of p53 gene mutation and bcl-2/bax proteins in drug resistance. Oncogene. 1996;12: 1055-1062.
7. Hanada M, Delia D, Aiello A, Stadmauer E, Reed JC. Bcl-2 gene hypomethylation and high level expression in B-cell chronic lymphocytic leukemia. Blood. 1993;82:1820-1828.
8. Horowitz MM, Messerer D, Hoelzer D, et al. Chemotherapy compared with bone marrow transplantation in adults with acute lymphoblastic leukemia in first remission. Ann Int Med. 1991;115: 13-18.
9. Srinivas G, Kusumakumary P, Nair MK, Panicker KR, Pilai MR. Bcl-2 protein and apoptosis in pediatric acute lymphoblastic leukemia. Int J Mol Med. 1998;1:755-759.
10. Hogarth LA, Hall AG. Increased Bax expression is associated with an increased risk of relapse in childhood acute lymphocytic leukemia. Blood. 1999;15:2671-2679.
11. Salomons GS, Smets LA, Verwijs-Janssen M, et al. Bcl-2 family members in childhood acute lymphoblastic leukemia: relationships with features at presentation, in vitro and in vivo response and long-term clinical outcome. Leukemia. 1999;10: 1574-1580.
12. Shao ZM, Dawson MI, Li XS, et al. p53 independent G0/G1 arrest and apoptosis induced by a novel retinoid in breast cancer cells. Oncogene. 1995;11:493-504.
13. Schadendorf D, Kern MA, Artue M, et al. Treatment of melanoma cells with the synthetic retinold CD437 induces apoptosis via activation of AP-1 in vitro, and causes growth inhibition in xenografts in vivo. J Cell Biol. 1996;135:1889-1898.
14. Oridate N, Higuchi M, Suzuki S, Shroot B, Hong WK, Lotan R. Rapid induction of apoptosis in human C33A cervical carcinoma cells by the synthetic retinoid 6-[3-(1-adamantyl)hydroxyphenyl]-2-naphtalene carboxylic acid (CD437). Int J Cancer. 1997;70:484-487.
15. Sun SY, Yue P, Shroot B, Hong WK, Lotan R. Induction of apoptosis in human non-small cell lung carcinoma cells by the synthetic retinoid CD437. J Cell Physiol. 1997;173:279-284.
16. Adachi H, Preston G, Harvat B, Dawson MI, Jetten AM. Inhibition of cell proliferation and induction of apoptosis by the retinoid AHPN in human lung carcinoma cells. Am J Respir Cell Mol Biol. 1998;18:323-333.
17. Evans TRJ, Kaye SB. Retinoids: present role and future potential. Br J Cancer. 1999;80:1-8.
18. Bernard BA, Bernardon JM, Delesclose C, et al. Identification of synthetic retinoids with selectivity for human nuclear retinoic acid receptor γ. Biochem Biophys Res Commun. 1992;186:977-983.
19. Hsu CA, Rishi AK, Su-Li X, et al. Retinoid induced apoptosis in leukemia cells through a retinoic acid nuclear receptor-independent pathway. Blood. 1997;89:4470-4479.
20. Jarpe MB, Widmann C, Knall C, et al. Anti-apoptotic versus pro-apoptotic signal transduction checkpoints and stop signs along the road to death. Oncogene. 1998;17:1475-1482.
21. Morrison RS, Kinoshita Y. p73-guilt by association. Science. 2000;289:257-258,
22. Mohammad RM, Mohamed AN, Hamden MY, et al. Establishment of a human B-CLL xenograft model; utility as a preclinical therapeutic model. Leukemia. 1996;10:130-137.
23. Rosenfield C, Goutner A, Choquet C, et al. Phenotypic characterisation of a unique non-T, non-B acute lymphoblastic leukaemia cell line. Nature. 1977;267:841-843.
24. Chao WR, Hobbs PD, Jong L, et al. Effects of receptor class- and subtype-selective retinoids and an apoptosis-inducing retinoid on the adherent growth of the NIH-OVCAR-3 ovarian cell line in culture. Cancer Lett. 1997;115:1-7.
25. Sheikh MS, Li X-S, Chen JC, Shao Z-M, Ordonez JV, Fontana JA. Mechanism of regulation of WAF1/CIP1 gene expression in human breast carcinoma: role of p53-dependent and independent signal transduction pathways. Oncogene. 1994, 9:3407-3415.
26. Gavrieli Y, Sherman Y, Ben-Sasson SA. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol. 1992;119:493-501.
27. Whitacre CM, Hashimato H, Tsai ML, Chatterjee S, Berger SL, Berger NA. Involvement of NAD poly(ADP-ribose) metabolism in p53 regulation and its consequences. Cancer Res. 1995;55: 3697-3701.
28. Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C. A novel assay for apoptosis: flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. 1995;184:39-51.
29. Woo M, Hakem R, Soengas MS, et al. Essential contribution of caspase 3/CPP32 to apoptosis and its associated nuclear changes. Genes Dev. 1998;12:806-819.
30. Wolf BB, Green DR. Suicidal tendencies: apoptotic cell death by caspase family proteases. J Biol Chem. 1999;29:20049-20052.
31. Widmann C, Gibson S, Johnson GL. Caspase-dependent cleavage of signalling proteins during apoptosis: a turn-off mechanism for anti-apoptotic signals. J Biol Chem. 1998;273:7141-7147.
32. Tewari M, Quan LT, O'Rourke K, et al. Yama/CPP32β, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase. Cell. 1995;81:801-809.
33. Gross A, McDonnel JM, Korsmeyer SJ. Bcl-2 family members and the mitochondria in apoptosis. Genes Dev. 1999;13:1899-1911.
34. Zhou P, Qian L, Kozopas KM, Craig RW. Mcl-1, a Bcl-2 family member, delays the death of hematopoietic cells under a variety of apoptosis-inducing conditions. Blood. 1997;89:630-643.
35. Boise LH, Garcia-Gonzalez M, Postema CE, et al. Bcl-X, a bcl-2 related gene that functions as a dominant regulator of cell death. Cell. 1993;74: 597-608.
36. L protein by caspase-3 like protease. Oncogene. 1998;17:1293-1307.
37. Huang DCS, Adams JM, Cory S. The conserved N-terminal BH4 domain of Bcl-2 homologues is essential for inhibition of apoptosis and interaction with CED-4. EMBO J. 1998;17:1029-1039.
38. Zhang Y, Hang Y, Dawson M, et al. Activation of the p38 and JNK/SAPK mitogen activated protein kinase pathways during apoptosis mediated by a novel retinoid. Exp Cell Res. 1999;247:233-240.
39. Zhang LX, Mills KJ, Dawson MI, Collins SJ, Jetten AM. Evidence for the involvement of RA receptor RARα-dependent-signalling pathways in the induction of tissue transglutaminase and apoptosis by retinoids. J Biol Chem. 1995;270:6022-6029.
40. Robertson KA, Emami B, Collins SJ. Retinoic acid-resistant HL-60R cells harbor a point mutation in the retinoic acid receptor ligand-binding domain that offers dominant negative activity. Blood. 1992;80:1885-1889.
41. Dawson MI, Chao WR, Pine P, et al., Correlation of retinoid binding affinity to RARα with retinoid inhibition of growth of estrogen-positive MCF-7 mammary carcinoma cells. Cancer Res. 1995;55: 4446-4451.
42. Seewald VL, Johnson BS, Parker MB, Collins SJ, Swisshelm K. Expression of retinoic acid receptor β mediates retinoic acid-induced growth arrest and apoptosis in breast cancer cells. Cell Growth Differ. 1995;6:1077-1088.
43. Liu Y, Lee M-O, Wang H-G, et al. RARβ mediates the growth-inhibitory effect of retinoic acid by inducing cell apoptosis in human breast cancer cells. Mol Cell Biol. 1996;16:1138-1149.
44. Lu X-P, Fanjul A, Picard N, Shroot B, Pfahl M. A selective reinoid with high activity against androgen resistant prostate cancer cell type. Int J Cancer. 1999;80:272-278.
45. Holmes WF, Dawson MI, Soprano D, Soprano KJ. Induction of apoptosis in ovarian cells by AHPN/CD437 is mediated by retinoid receptors. J Cell Physiol. 2000;185:61-67.
46. Heyman RA, Mangelsdorf DJ, Duck JA, et al. 9-cis retinoic acid is a high affinity ligand for the retinoid X receptor. Cell. 1992;68:397-406.
47. Levin AA, Sturzenbecker LJ, Kazmer S, et al. 9-cis retinoic acid stereoisomer binds and activates the nuclear receptor RXR alpha. Nature. 1992;355:359-361.
48. Krajewski S, Gascoyne RD, Zapata JM, et al. Immunolocalization of the ICE/Ced-3 family protease CPP32 (caspase-3) in non-Hodgkin's lymphomas, chronic lymphocytic leukemias and reactive lymph nodes. Blood. 1997;89:3817-3825.
49. Bellosillo B, Dalmau M, Colmer D, Gil J. Involvement of CED-3/ICE proteases in the apoptosis of B-chronic lymphocytic leukemia cells. Blood. 1997;89:3378-3384.
50. Kitada S, Andersen J, Akar S, et al. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with in vitro and in vivo chemoresponses. Blood. 1998;91:3379-3389.
51. Minn AJ, Rudin CM, Boise LH, Thompson CB. Expression of bcl-XL can confer a multidrug resistance phenotype. Blood. 1995;86:1903-1910.
52. Schmitt E, Cimoli G, Steyaert A, Bertrand R. Bcl-xl modulates apoptosis induced by anticancer drugs and delays DEVDase and DNA fragmentation-promoting activities. Exp Cell Res. 1998;240: 107-121.
53. Bae J, Leo CP, Hsu SY, Hsueh AJW. MCL-1S, a spicing variant of the antiapoptotic Bcl-2 family member MCL-1, encodes a proapoptotic protein possessing only the BH3 domain. J Biol Chem. 2000;275:25255-25261.
54. Hunter JJ, Parslow TG. Functional dissection of the human bcl-2 protein: sequence requirement for inhibition of apotosis. Mol Cell Biol. 1996;16: 877-883.
55. Borner C, Martinou I, Mattman C, et al. The protein bcl-2 alpha does not require membrane attachment, but two conserved domains to suppress apoptosis. J Cell Biol. 1994;126:1059-1068.
56. Clem RJ, Cheng EH, Karp CL, et al. Modulation of cell death by Bcl-XL through caspase interaction. Proc Natl Acad Sci U S A. 1998;95:554-559.
57. Verheij M, Bose R, Lin XH, et al. A requirement for ceremide-initiated SAPK/JNK signalling in stress induced apoptosis. Nature. 1996;380:75-79.
58. Davis RJ. Signal transduction by the JNK group of MAP kinases. Cell. 2000;103:239-252.
59. Kuan CY, Yang DD, Samanta Roy DR, Davis RJ, Rakic P, Flavell RA. The Jnk1 and Jnk2 protein kinases are required for regional specific apoptosis during early brain development. Neuron. 1999;22:667-676.
60. Sabapathy K, Jochum W, Hochedlinger K, Chang L, Karin M, Wagner EF. Defective neural tube morphogenesis and altered apoptosis in the absence of both JNK1 and JNK2. Mech Dev. 1999; 89:115-124.
61. Tournier C, Hess P, Yang DD, et al. Requirement of JNK for stress-induced activation of the cytochrome c-mediated death pathway. Science. 2000;288:870-874.
62. Mohammad RM, Varterasian ML, Almatchy VP, Hannoudi GN, Pettit GR, Al-Katib A. Successful treatment of human chronic lymphocytic leukemia xenografts with combination biological agents auristatin PE and bryostatin 1. Clin Cancer Res. 1998;4:1337-1343.
63. Binet JL, Auguier A, Dighiero G, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer. 1981;48:198-216.
64. Montserrat E, Gomis F, Vallespi T, et al. Presenting features and prognosis of chronic lymphocytic leukemia in young adults. Blood. 1991;78:1545-1551.
65. Lee JS, Dixon DO, Kantarjian HM, Keating MJ, Talpaz M. Prognosis of chronic lymphocytic leukemia: a multivariate analysis of 325 untreated patients. Blood. 1987;69:929-936.
66. Montserrat E, Rozman C. Chronic lymphocytic leukemia: prognostic factors and natural history. Bailleres Clin Haematol. 1993;6:849-866.